ASO-Δ2 modulation of NLRP3 exon 2 splicing decreases IL-1β release in hMDMs from patients with CAPS (Supplemental Fig. 4), confirming ASO activity in human primary cells and offering promise for ASO-mediated exon skipping effectiveness in mitigating inflammasome signaling in disease-relevant cells. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.